https://doi.org/10.4081/hmr.v1i8.299

Gemcitabine: from solid tumor to hematology?

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 147
PDF: 392
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

PL Zinzani
support@pagepress.org
M Tani
V Stefoni
E Marchi
M Fina
L Alinari
Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) is an analog of deoxycytidine. It is transformed to the active triphosphate(dFdCTP) after intracellular phosphorylation. Gemcitabine monophosphate is inserted into the DNA and inhibits DNA elongation as a false nucleotide. In contrast to other antimetabolites, an additional, altered nucleotide is inserted behind dFdC inhibiting repair mechanisms (masked chain termination). By this, repair enzymes (exonucleases) of the DNA are inhibited and repair mechanisms are prevented. This factor, as well as enzymic inhibition of gemcitabine diphosphate, lead to high intracellular concentrations of gemcitabine and enforce the cytostatic effect. Gemcitabine is mostly inserted into DNA but partly also into RNA. Competition at the receptor with the nucleoside deoxycytidine phosphate (dCTP) leads to a competitive inhibition of DNA polymerases.1

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Zinzani, P., Tani, M., Stefoni, V., Marchi, E., Fina, M., & Alinari, L. (2009). Gemcitabine: from solid tumor to hematology?. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.299
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).